Edwards Lifesciences Corp.

The Irvine provider of products and services to treat cardiovascular disease said net income for the first quarter was $14.2 million, or 24 cents a share, which excluded a $1.5 million reduction from an accounting change. A year ago, the company’s pro forma net income totaled $9.1 million, or 16 cents a share, which excluded nonrecurring expenses. Sales dropped 3% to $191.9 million.

The company was spun off last April from Baxter International Inc.